Movement Alert｜10x Genomics, Inc. Rises 5.01% in Regular Trading, RBC Initiates Coverage With $70 Target Price Well Above Consensus

Market Focus

Yesterday

On September 9, 10x Genomics, Inc. rose 5.01% in regular trading, trading at $65.85 per share, with turnover of approximately $83.81 million. The rally was primarily driven by RBC Capital Markets initiating coverage with a Sector Perform rating and a $70 price target, significantly above the analyst consensus mean of $51.

RBC highlighted 10x Genomics, Inc. as a leader in high-plex spatial molecular profiling, commanding over 60% market share. The firm noted the spatial business remains in early-stage adoption, sustaining double-digit growth even ahead of the upcoming Atera product launch. However, RBC also flagged that single-cell represents a structural growth dampener, with double-digit price-per-reaction declines partially offset by volume growth. Additionally, a recently disclosed 13G/A filing revealed notable institutional position adjustments, further bolstering market confidence. The company also recently beat Q2 estimates, posting EPS of -$0.14 versus the -$0.24 consensus, and raised full-year revenue guidance to $610 million-$630 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1183048911"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183048911\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183048911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183048911","market":"hk","top_or_hot":-1,"title":"Movement Alert｜10x Genomics, Inc. Rises 5.01% in Regular Trading, RBC Initiates Coverage With $70 Target Price Well Above Consensus","media":"Market Focus","content":"<p><p>On September 9, 10x Genomics, Inc. rose 5.01% in regular trading, trading at $65.85 per share, with turnover of approximately $83.81 million. The rally was primarily driven by RBC Capital Markets initiating coverage with a Sector Perform rating and a $70 price target, significantly above the analyst consensus mean of $51.</p><p>RBC highlighted 10x Genomics, Inc. as a leader in high-plex spatial molecular profiling, commanding over 60% market share. The firm noted the spatial business remains in early-stage adoption, sustaining double-digit growth even ahead of the upcoming Atera product launch. However, RBC also flagged that single-cell represents a structural growth dampener, with double-digit price-per-reaction declines partially offset by volume growth. Additionally, a recently disclosed 13G/A filing revealed notable institutional position adjustments, further bolstering market confidence. The company also recently beat Q2 estimates, posting EPS of -$0.14 versus the -$0.24 consensus, and raised full-year revenue guidance to $610 million-$630 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜10x Genomics, Inc. Rises 5.01% in Regular Trading, RBC Initiates Coverage With $70 Target Price Well Above Consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜10x Genomics, Inc. Rises 5.01% in Regular Trading, RBC Initiates Coverage With $70 Target Price Well Above Consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-09 01:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 9, 10x Genomics, Inc. rose 5.01% in regular trading, trading at $65.85 per share, with turnover of approximately $83.81 million. The rally was primarily driven by RBC Capital Markets initiating coverage with a Sector Perform rating and a $70 price target, significantly above the analyst consensus mean of $51.</p><p>RBC highlighted 10x Genomics, Inc. as a leader in high-plex spatial molecular profiling, commanding over 60% market share. The firm noted the spatial business remains in early-stage adoption, sustaining double-digit growth even ahead of the upcoming Atera product launch. However, RBC also flagged that single-cell represents a structural growth dampener, with double-digit price-per-reaction declines partially offset by volume growth. Additionally, a recently disclosed 13G/A filing revealed notable institutional position adjustments, further bolstering market confidence. The company also recently beat Q2 estimates, posting EPS of -$0.14 versus the -$0.24 consensus, and raised full-year revenue guidance to $610 million-$630 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1183048911","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183048911","pubTimestamp":1788888122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 9, 10x Genomics, Inc. rose 5.01% in regular trading, trading at $65.85 per share, with turnover of approximately $83.81 million. The rally was primarily driven by RBC Capital Markets...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"走势警报|10x Genomics, Inc. 常规交易上涨 5.01%，加拿大皇家银行启动覆盖，目标价 70 美元，远高于市场共识","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"On September 9, 10x Genomics, Inc. rose 5.01% in regular trading, trading at $65.85 per share, with turnover of approximately $83.81 million. The rally was primarily driven by RBC Capital Markets initiating coverage with a Sector Perform rating and a $70 price target, significantly above the analyst consensus mean of $51.RBC highlighted 10x Genomics, Inc. as a leader in high-plex spatial molecular profiling, commanding over 60% market share. The firm noted the spatial business remains in early-stage adoption, sustaining double-digit growth even ahead of the upcoming Atera product launch. However, RBC also flagged that single-cell represents a structural growth dampener, with double-digit price-per-reaction declines partially offset by volume growth. Additionally, a recently disclosed 13G/A filing revealed notable institutional position adjustments, further bolstering market confidence. The company also recently beat Q2 estimates, posting EPS of -$0.14 versus the -$0.24 consensus, and raised full-year revenue guidance to $610 million-$630 million.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}